|With major facilities in Australia, Germany, Switzerland, United Kingdom and the U.S., CSL has more than 17,000 employees working in over 30 countries.|
Contact CSL to find your nearest CSL business
For many serious and life-saving medical products, we are a partner of choice for many companies around the world.
Headquarters in Melbourne Australia, the CSL Group includes:
CSL Behring incorporating
Key Business areas
Research and Development
In 2015/16, we invested over US$614m in research and development activities. Our centres of excellence are located around the world and they focus on:
- Developing new products
- Improving and expanding the medical use of existing products
Find out more about
Research & Development
CSL is a leading manufacturer in a US$24 billion plasma industry. A continual focus on innovation in new products, improved products and manufacturing know how is the key to future growth.
The key businesses involved with plasma products include:
CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collection networks through
CSL Behring is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan.
Vaccines and pharmaceuticals
In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus.
Seqirus is the world’s no. 2 influenza vaccine provider in sales with operations in more than 20 countries in the US$4 billion global industry. Seqirus provides a differentiated product portfolio, possesses strong pandemic and prepandemic franchises and manages one of the world’s largest influenza vaccine manufacturing networks with operations on three continents: North America, Europe, and Australia. CSL’s experience with influenza dates back nearly 100 years when it produced vaccine during the Spanish Flu pandemic in 1919.
In addition to providing influenza vaccines worldwide,
Seqirus manufactures, sells and distributes a comprehensive range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. We also manufacture and market in vitro diagnostic products through